Targeted therapy for metastatic renal cell Carcinoma: Overview Chapter uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Boronic Acids
  • Carcinoma, Renal Cell
  • Kidney Medulla
  • Kidney Neoplasms
  • Pyrazines

abstract

  • The treatment of advanced renal cell carcinoma has evolved over the last decade, and currently a new treatment paradigm utilizing a variety of targeted approaches is in place. Novel agents including sunitinib, sorafenib, temsirolimus, and bevacizumab are utilized for patients with advanced and metastatic clear cell carcinoma. Inhibition of a variety of targets including kinase receptors and their ligands such as vascular endothelial cell growth factor (VEGF), or the intracellular kinase mTOR (mammalian target of rapamycin) are in part responsible for the effects of these agents. The clinical trials responsible for these advances as well as the evolving treatment paradigm are reviewed in this introduction. © 2009 Humana Press.

publication date

  • December 2009

Research

keywords

  • Book Chapter

Identity

Digital Object Identifier (DOI)

  • 10.1007/978-1-59745-332-5_1

Additional Document Info

start page

  • 1

end page

  • 12